Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
120 participants
INTERVENTIONAL
2013-03-01
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
NCT01883180
Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
NCT05166967
Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation
NCT02643589
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
NCT04778618
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
NCT03689465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
ATG-F treated
Immunosuppressive Agent
ATG-Fresenius versus ATG
Arm 2
ATG treated
Immunosuppressive Agent
ATG-Fresenius versus ATG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunosuppressive Agent
ATG-Fresenius versus ATG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged \<65 years
* Patients undergoing Haplo-identical hematopoietic stem cell transplantation.
* Cardiac: Left ventricular ejection fraction ≥ 50%
* Adequate renal and hepatic function
* Performance status: Karnofsky ≥ 70%
Exclusion Criteria
* Any co-morbidity precluding the administration of ATG or ATG-F.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ting YANG
Prof.M.D.Ph.D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATG-F VS ATG-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.